⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
IONS
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
businesswire.com
IONS
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
businesswire.com
IONS
Form 8-K
sec.gov
IONS
ATTR Early-Career Research Forum Opens National Call for Abstracts; Two $100,000 Wiesman Awards to Be Granted
prnewswire.com
AZN
IONS
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
businesswire.com
IONS
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia USA - English USA - English
prnewswire.com
IONS
New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
prnewswire.com
IONS
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight
globenewswire.com
IONS
ALNY
NVS
BIIB
ARWR
SLN
WVE
VNDA
NSP
TCRT
AMX
CDIO
SRPT
VIR
BNTX
ARCT
GSK
PFE
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
businesswire.com
IONS
BIIB